BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16155018)

  • 21. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple myeloma: charging toward a bright future.
    Katzel JA; Hari P; Vesole DH
    CA Cancer J Clin; 2007; 57(5):301-18. PubMed ID: 17855486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
    Björkstrand B; Gahrton G
    Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New treatment strategy of multiple myeloma for cure].
    Murakami H; Handa H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of stem cell transplantation.
    Harousseau JL
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug insight: thalidomide as a treatment for multiple myeloma.
    Kumar S; Anderson KC
    Nat Clin Pract Oncol; 2005 May; 2(5):262-70. PubMed ID: 16264962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokines and signal transduction.
    Hideshima T; Podar K; Chauhan D; Anderson KC
    Best Pract Res Clin Haematol; 2005; 18(4):509-24. PubMed ID: 16026734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
    Podar K; Richardson PG; Chauhan D; Anderson KC
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tandem bone marrow transplantation in multiple myeloma.
    Musto P
    N Engl J Med; 2004 Apr; 350(14):1466-7; author reply 1466-7. PubMed ID: 15074004
    [No Abstract]   [Full Text] [Related]  

  • 33. [Multiple myeloma--advances in disease biology and implications for therapy].
    Chou T
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1206-12. PubMed ID: 11579631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.
    Siegel DS
    Semin Hematol; 2012 Jul; 49 Suppl 1():S3-15. PubMed ID: 22727390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment strategies in follicular lymphomas: current status and future perspectives.
    Hiddemann W; Buske C; Dreyling M; Weigert O; Lenz G; Forstpointner R; Nickenig C; Unterhalt M
    J Clin Oncol; 2005 Sep; 23(26):6394-9. PubMed ID: 16155025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma.
    Asosingh K
    Verh K Acad Geneeskd Belg; 2003; 65(2):127-34. PubMed ID: 12870183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
    Klepin HD; Hurd DD
    Bone Marrow Transplant; 2006 Nov; 38(9):585-92. PubMed ID: 16953209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma.
    Alici E; Björkstrand B; Treschow A; Aints A; Smith CI; Gahrton G; Dilber MS
    Cancer Gene Ther; 2007 Mar; 14(3):227-32. PubMed ID: 17082794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted treatments to improve stem cell outcome: old and new drugs.
    Raab MS; Breitkreutz I; Anderson KC
    Bone Marrow Transplant; 2007 Dec; 40(12):1129-37. PubMed ID: 17768392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
    Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
    Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.